Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1162 | 1026 | 1218 | 1221 | 1565 | 2062 |
Fund Return | 16.2% | 2.62% | 21.75% | 6.89% | 9.37% | 7.51% |
Place in category | 93 | 471 | 124 | 424 | 485 | 166 |
% in Category | 4 | 18 | 5 | 23 | 31 | 13 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GS India Equity Portfolio E Acc | 4.99B | 22.24 | 11.40 | 12.69 | ||
Goldman Sachs Global CORE Equity Pe | 4.53B | 18.13 | 7.30 | 10.43 | ||
GS Global CORE Equity Portfolio E C | 4.53B | 18.70 | 7.35 | 10.42 | ||
GS Global CORE Equity Portfolio I E | 4.53B | 19.73 | 8.75 | 11.88 | ||
GS EM Equity Portfolio E Acc | 3.36B | 9.66 | -7.67 | 4.13 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund A Acc EUR | 160.91M | 13.84 | 5.12 | 5.56 | ||
European Growth Fund E Acc EUR | 21.11M | 13.26 | 4.34 | 4.77 | ||
European Growth Fund Y Acc EUR | 144.21M | 14.46 | 6.03 | 6.43 | ||
European Growth Fund Y DIST EUR | 66.23M | 14.45 | 6.02 | 6.43 | ||
European Growth Fund A DIST Eue | 6.61B | 13.82 | 5.11 | 5.56 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 5.40 | 810.2 | -2.95% | |
ASML Holding | NL0010273215 | 3.95 | 759.40 | -0.05% | |
Nestle | CH0038863350 | 3.36 | 85.34 | +0.61% | |
Roche Holding Participation | CH0012032048 | 3.35 | 271.20 | +0.22% | |
SAP | DE0007164600 | 3.07 | 201.725 | -1.36% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review